But, it doesn't matter since it will be free. Bausch Health Companies Inc's P/E ratio is -11.76. The remaining 80% is being used as collateral for BHC's 20B+ debt. I have no business relationship with any company whose stock is mentioned in this article. This DCF yields a valuation of approximately $10.2 billion for BLCO (FCF multiple of 16). She is a FINRA Series 7, 63, and 66 license holder. This information, taken in isolation, makes BHC stock look like a stark-raving no-brainer that will allow you to team up with Carl Icahn (who owns over 9% of BHC) to make money on a stock that has stumped some of the greatest investors of our time (such as Bill Ackman). As mentioned, compared to the more established parent company, the subsidiary's stock price is more volatile and subject to market whims. Thus far, BHC has not yet IPOed Solta Medical and has only sold 10% of its stake in BLCO and is still planning on selling an additional 10% in the open market. CNBC's Jim Cramer also valued BLCO at $21 billion. The spinoff will get a new name and a new management (unless it had an experienced management in place prior to the spinoff). Ultimately, spinoffs tend to perform well over time. BHC) shareholders are up 19% this past week, but still in the red over the last three years (Simply Wall St.) Dec-27-22 08:49AM: . Seeking Alpha's Disclosure: Past performance is no guarantee of future results. Historically, spinoffs have been good for investors. The plunge of $4.04, or 24.08 per cent, to $12.74 in late-morning trading on the Toronto Stock Exchange came on the final day of its initial public offering for eye . Bausch Health Cos. Inc. BHC, -0.30% filed for an initial public offering of its Bausch & Lomb Corp. unit on Thursday, with plans to list on the New York Stock Exchange, under the ticker "BLCO." The offering is for 35M shares. Bausch + Lomb (BLCO) Scheduled to Post Earnings on Wednesday And what else do you need to know? In case any of these happen, I'm happy to hold BHC or Bausch and Lomb spinoff until the value is realized. Revenue for the quarter ended March 31 totalled US$1.92 billion, down from US$2.03 billion in the same period last year. Here's what that means for investors. GX Acquisition Corp. - DEF 14A - Proxy Statement - May 01, 2023 After BHC has disposed of these businesses it will likely have raised over $7 billion and exceeded its goal of 6.5-1 debt-to-EBITDA margin. Jobs In Rosslyn Pretoria, The eye health products company is a wholly-owned subsidiary of Bausch Health Companies Inc. (TSX:BHC), and reports of its IPO plan had started surfacing last year. BHC is almost certainly going to decline in price immediately after the distribution of BLCO not just for the technical reasons outlined above, but because it is separating from arguably its most valuable business. The highly anticipated Bausch + Lomb(NYSE:BLCO) initial public offering (IPO) is now a reality, and BLCO stock is now trading. Bausch + Lomb rose about 3% in Friday's trading but remained well below its disappointing IPO price of $18. She has been an investor, entrepreneur, and advisor for more than 25 years. It can also be calculated by dividing the company's Market Cap by the Net Profit. Bausch + Lomb ( NYSE:BLCO - Get Rating) last released its quarterly earnings results on Wednesday, February 22nd. The remaining Bausch and Lomb shares will be distributed to shareholders. The Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 5,250,000 common shares of Bausch + Lomb to cover over-allotments, if any, at the initial public. Accordingly, this deal was largely seen as a way to unlock shareholder value. At a share price of $15.66, this amounts to a market cap of $5.48 billion, which again, BHC still owns roughly 90% of. outsized gains. His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective. Tealight Candle Holders Bulk, Spinoffs shares can lose value for a period of time after the new company is created for other reasons, as well. Cyber Warfare Examples 2021, Get the latest Bausch Health Companies Inc. (BHC) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. BLCO Stock IPO: When Does Bausch + Lomb Go Public? BHC further states that the partnership agreement provides that either partner may pursue another network only if "the full interest" is "offered to the partnership." BHC Bausch Health Companies Inc - Stocktwits The Second Amendment provides for a new term facility with an aggregate principal amount of $2,500 million (the "2027 Term Loan B Facility") maturing on February 15, 2027 and a new revolving credit facility of $975 million (the "2027 Revolving Credit Facility") that will mature at the earlier of February 15, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of Bausch Health and Bausch Health Americas, Inc. ("BHA"), a wholly owned subsidiary of Bausch Health, in an aggregate principal amount in excess of $1,000 million.
Share this article